These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 42629)

  • 21. [Comparative research on some clinical and psychopharmacological parameters of reactive paranoid psychoses].
    Masiak M; Marmurowska-Michałowska H; Nagay J; Olajossy M; Perzyński J; Wysocka A
    Psychiatr Pol; 1993; 27(1):63-74. PubMed ID: 8098150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Bromperidol decanoate in the residual phase of schizophrenia].
    Smeraldi E; Cocconcelli C; Canova L; Faravelli C; Marchetti FP; Mariani G; Rapisarda V
    Minerva Psichiatr; 1996 Mar; 37(1):39-44. PubMed ID: 8926856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation of a rational pharmacotherapy intervention for inpatients at a psychiatric department.
    Sorensen L; Nielsen B; Stage KB; Brøsen K; Damkier P
    Nord J Psychiatry; 2008; 62(3):242-9. PubMed ID: 18622885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depressive symptoms and schizophrenia a psychopharmacological approach.
    Mauri MC; Bravin S; Fabiano L; Vanni S; Boscati L; Invernizzi G
    Encephale; 1995; 21(5):555-8. PubMed ID: 8529564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002.
    Centorrino F; Fogarty KV; Sani G; Salvatore P; Cincotta SL; Hennen J; Guzzetta F; Talamo A; Saadeh MG; Baldessarini RJ
    Hum Psychopharmacol; 2005 Oct; 20(7):485-92. PubMed ID: 16116665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics?
    Henkel V; Mergl R; Schäfer M; Rujescu D; Möller HJ; Hegerl U
    Pharmacopsychiatry; 2004 May; 37(3):110-8. PubMed ID: 15138894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Improvement criteria after neuroleptic treatment and clinical and neuroradiological factors in schizophrenic psychoses. Preliminary studies].
    Jarema M; Choma M; Poniatowska R; Krawczyk R; Kozłowski P
    Psychiatr Pol; 1997; 31(1):21-32. PubMed ID: 9527652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tolerance of bromperidol in long term application].
    Scelovic B
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():38-40. PubMed ID: 35477
    [No Abstract]   [Full Text] [Related]  

  • 29. Antipsychotic effects, side effects and effective dosis of the butyrophenone lenperone (AHR 2277).
    Woggon B; Franke A; Hucker H; Ruether E; Athen D; Angst J; Hippius H
    Int Pharmacopsychiatry; 1977; 12(2):113-26. PubMed ID: 561037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement in refractory psychosis with dronabinol: four case reports.
    Schwarcz G; Karajgi B
    J Clin Psychiatry; 2010 Nov; 71(11):1552-3. PubMed ID: 21114952
    [No Abstract]   [Full Text] [Related]  

  • 31. Antipsychotic efficacy of fluperlapine. An open multicenter trial.
    Woggon B; Angst J; Bartels M; Heinrich K; Hippius H; Koukkou M; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pöldinger W
    Neuropsychobiology; 1984; 11(2):116-20. PubMed ID: 6148712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol.
    Pöldinger W; Bures E; Haage H
    Int Pharmacopsychiatry; 1977; 12(3):184-92. PubMed ID: 334688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neuroleptic potency of bromperidol].
    Kaumeier S; Haase HJ; Schwarz H; Gundel A; Linde OK; Maetz H; Scheel R; Stripf A; Stripf L
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():41-4. PubMed ID: 35478
    [No Abstract]   [Full Text] [Related]  

  • 34. Double-blind comparison of bromperidol and perphenazine.
    Woggon B; Angst J
    Int Pharmacopsychiatry; 1978; 13(3):165-76. PubMed ID: 355182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Speech production in schizophrenia: preliminary data regarding voice onset time.
    Epstein-Lubow G; Hochstadt J; Lieberman P; Kaplan GB
    Schizophr Res; 2006 Feb; 82(2-3):267-9. PubMed ID: 16371248
    [No Abstract]   [Full Text] [Related]  

  • 36. Gender differences in antipsychotic prescribing.
    Smith S
    Int Rev Psychiatry; 2010; 22(5):472-84. PubMed ID: 21047160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Negative parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited.
    Peralta V; Cuesta MJ
    Schizophr Res; 1999 Dec; 40(3):245-53. PubMed ID: 10638863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Psychoses during various ages].
    Lôo H
    Encephale; 2011 Sep; 37(4 Suppl 4):H1-2. PubMed ID: 22108179
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of efficacy of timiperone, a new butyrophenone derivative, and clocapramine in schizophrenia: a multiclinic double-blind study.
    Nakazawa T; Ohara K; Sawa Y; Edakubo T; Matsui H; Sawa J; Kawaguchi K; Hattori S; Nakajima M
    J Int Med Res; 1983; 11(5):247-58. PubMed ID: 6139317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of psychosis subsequent to phenothiazine-induced agranulocytosis.
    Ananth JV; Beszterczey A
    Compr Psychiatry; 1973; 14(4):319-23. PubMed ID: 4146801
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.